Results 171 to 180 of about 9,610,175 (344)

Survivin and Aurora Kinase A control cell fate decisions during mitosis

open access: yesMolecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir   +2 more
wiley   +1 more source

Mechanisms of the Ershiwuwei Guijiu Pill in Treating Postmenopausal Osteoporosis Based on Network Analysis and Experimental Validation

open access: yesJournal of Evidence-Based Integrative Medicine
Background The Tibetan medicine Ershiwuwei Guijiu Pill (EWGP), a classic Tibetan medicine prescription for the treatment of postmenopausal osteoporosis (PMOP) in the Qinghai–Tibet region, has attracted extensive attention due to its curative effects on ...
Fanglin Duan   +9 more
doaj   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

open access: yesMolecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He   +8 more
wiley   +1 more source

MRI-based detailed evaluation of the anatomy of the human coccyx among Turkish adults

open access: diamond, 2017
Hasan Tetiker   +5 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

open access: yesMolecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy